Adaptive is comercial-stage company. Co is advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Co.'s clinical diagnostic product, clonoSEQ, is the test authorized by the Food and Drug Administration for the detection and monitoring of minimal residual disease in patients with multiple myeloma and B cell acute lymphoblastic leukemia and is being validated for patients with other blood cancers. Co.'s commercial research product, immunoSEQ, primarily serves as its underlying research and development engine to develop and validate its clinical pipeline. The ADPT stock yearly return is shown above.
The yearly return on the ADPT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ADPT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|